Dudakova, Anna

[["dc.bibliographiccitation.firstpage","4356"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Antimicrobial Agents and Chemotherapy"],["dc.bibliographiccitation.lastpage","4359"],["dc.bibliographiccitation.volume","59"],["dc.contributor.author","Bader, Oliver"],["dc.contributor.author","Tuennermann, Jana"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Tangwattanachuleeporn, Marut"],["dc.contributor.author","Weig, Michael S."],["dc.contributor.author","Gross, Uwe"],["dc.date.accessioned","2018-11-07T09:54:53Z"],["dc.date.available","2018-11-07T09:54:53Z"],["dc.date.issued","2015"],["dc.description.abstract","Azole antifungal drug resistance in Aspergillus fumigatus is an emerging problem in several parts of the world. Here we investigated the distribution of such strains in soils from Germany. At a general positivity rate of 12%, most prevalently, we found strains with the TR34/L98H and TR46/Y121F/T289A alleles, dispersed along a corridor across northern Germany. Comparison of the distributions of resistance alleles and genotypes between environment and clinical samples suggests the presence of local clinical clusters."],["dc.description.sponsorship","Pfizer Pharma Germany [WS2275398]"],["dc.identifier.doi","10.1128/AAC.00100-15"],["dc.identifier.isi","000360896000088"],["dc.identifier.pmid","25941229"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36631"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Microbiology"],["dc.relation.issn","1098-6596"],["dc.relation.issn","0066-4804"],["dc.title","Environmental Isolates of Azole-Resistant Aspergillus fumigatus in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.contributor.author","Hosseini, S. S. Justus"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Kummer, Karsten"],["dc.contributor.author","Zschüntzsch, Jana"],["dc.date.accessioned","2022-09-01T09:51:24Z"],["dc.date.available","2022-09-01T09:51:24Z"],["dc.date.issued","2022"],["dc.description.abstract","Zusammenfassung\n \n Einer erfolgreichen Impfung (adäquater Anstieg der Anti-S[Spike]-Protein-Antikörper) gegen SARS-CoV‑2 (engl.\n severe acute respiratory syndrome coronavirus type 2\n ) wird ein suffizienter Schutz gegen einen schweren Verlauf von COVID-19 (engl.\n coronavirus disease 2019\n ) zugeschrieben. Bei Patient*innen mit chronisch-inflammatorischen Erkrankungen (engl.\n „chronic inflammatory diseases“\n [CID]) und Immunsuppression ist der Impferfolg weiterhin im wissenschaftlichen Diskurs. Daher evaluierten wir bei Patient*innen mit einer neuromuskulären Erkrankung (NME), die zu regelmäßigen Infusionen von Immunglobulinen in unserer neurologischen Tagesklinik/Ambulanz vorstellig wurden, 2 Wochen nach vollständiger Immunisierung die Antikörpertiter gegen das S1 (S1-Untereinheit des Spike-Proteins) -Antigen von SARS-CoV‑2. Unsere Daten zeigen, dass Patient*innen mit einer chronischen autoimmunen NME und gleichzeitiger immunsuppressiver bzw. immunmodulierender Therapie nach einer Impfung sowohl mit einem mRNA- als auch mit einem Vektorimpfstoff eine Antikörperantwort aufwiesen. Im Vergleich zu gesunden Proband*innen zeigte sich eine vergleichbare Anzahl an Serokonversionen durch die Impfung. Eine Korrelation zwischen Immunglobulindosierung und Impfantwort sowie Infusionsintervall und Impfantwort ließ sich nicht feststellen. Demgegenüber zeigte jedoch insbesondere die Kombination aus Mycophenolatmofetil (MMF) und Prednisolon eine signifikante Reduktion der spezifischen Antikörpersynthese."],["dc.description.abstract","Abstract\n Successful vaccination (adequate elevation of anti-spike protein antibodies) is attributed with sufficient protection against a severe course of coronavirus disease 2019 (COVID-19). For patients with chronic inflammatory diseases (CID) and immunosuppression the success of vaccination is an ongoing scientific discourse. Therefore, we evaluated the antibody titer against the S1 antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 2 weeks after complete immunization in patients with an underlying neuromuscular disease (NMD), who presented to our neurological day clinic and outpatient department for regular infusions of immunoglobulins. The data show that patients with chronic autoimmune NMD and simultaneous immunosuppressive or immune modulating treatment show an antibody response after vaccination with both mRNA and vector vaccines. In comparison to healthy subjects there is a comparable number of seroconversions due to the vaccination. A correlation between immunoglobulin dose and vaccination response could not be found; however, in contrast, there was a significant reduction of specific antibody synthesis, especially for the combination of mycophenolate mofetil (MMF) and prednisolone."],["dc.identifier.doi","10.1007/s00115-022-01363-6"],["dc.identifier.pii","1363"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113955"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1433-0407"],["dc.relation.issn","0028-2804"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","SARS-CoV-2-Antikörper-Antwort auf die zweite COVID-19-Impfung bei neuromuskulären Patienten unter immunmodulierender Therapie"],["dc.title.translated","SARS-CoV-2 antibody response to the second COVID-19 vaccination in neuromuscular disease patients under immune modulating treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","The Thoracic and Cardiovascular Surgeon"],["dc.contributor.author","Saha, Shekhar"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Kutschka, Ingo"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Niehaus, Heidi"],["dc.date.accessioned","2022-04-01T10:02:45Z"],["dc.date.available","2022-04-01T10:02:45Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract Objective The rising incidence of infective endocarditis (IE) accompanied by the de-escalation of antibiotic prophylaxis and the complexity of surgical treatment makes IE a daunting foe. We reviewed all patients who underwent cardiac surgery for IE at our institution with a focus on causative organisms and infective foci. Methods A review of 3,952 consecutive patients who underwent cardiac surgery at our institution between January 2013 and December 2017 revealed 160 patients (4%) who were operated for IE. Results The predominantly affected valves were the aortic (30%) and mitral valve (26.9%) as well as a combination of both (8.8%). A total of 28.8% of patients suffered from prosthetic valve endocarditis (PVE). The most frequently identified causative organisms were Staphylococcus (45.7%), Streptococcus (27.5%), and Enterococcus species (16.7%), which was predominantly associated with PVE (p = 0.050). In 13.1% of patients, a causative organism has not been detected. The most frequent infective foci were dental (15%), soft-tissue infections (15%), spondylodiscitis (10%), and infected intravascular implants (8.8%). Relevant predisposing factors were immunosuppression (9.4%) and intravenous drug abuse (4.4%). Septic cerebral infarctions were diagnosed in 28.8% of patients. Postoperative mortality was 22.5%. Conclusions As the bacterial spectrum and the infective foci are still the “old acquaintances,” and with regard to the increasing incidence of IE, current risk–benefit evaluations concerning antibiotic prophylaxis may need to be revisited."],["dc.identifier.doi","10.1055/s-0041-1740540"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105997"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1439-1902"],["dc.relation.issn","0171-6425"],["dc.title","Bacterial Spectrum and Infective Foci in Patients Operated for Infective Endocarditis: Time to Rethink Strategies?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1065"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical Microbiology Reviews"],["dc.bibliographiccitation.lastpage","1091"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Spiess, Birgit"],["dc.contributor.author","Tangwattanachuleeporn, Marut"],["dc.contributor.author","Sasse, Christoph"],["dc.contributor.author","Buchheidt, Dieter"],["dc.contributor.author","Weig, Michael"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Bader, Oliver"],["dc.date.accessioned","2020-12-10T18:36:52Z"],["dc.date.available","2020-12-10T18:36:52Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1128/CMR.00095-16"],["dc.identifier.eissn","1098-6618"],["dc.identifier.issn","0893-8512"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76764"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Microbiology"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Gómez-Molero, Emilia"],["dc.contributor.author","Willis, Jesse R."],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Carreté, Laia"],["dc.contributor.author","Weig, Michael"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Gácser, Attila"],["dc.contributor.author","Gabaldón, Toni"],["dc.contributor.author","Bader, Oliver"],["dc.date.accessioned","2021-04-14T08:32:38Z"],["dc.date.available","2021-04-14T08:32:38Z"],["dc.date.issued","2020"],["dc.description.abstract","The human pathogenic yeast Candida parapsilosis has gained significant importance over the past decades as one of the principal causes of fungal bloodstream infections. Isolates of C. parapsilosis are known to be able to switch between several different colony morphologies in vitro, which are correlated with different cell shapes, altered cell surface properties, and thus different capacities to form biofilms on indwelling medical devices. In a set of six clinical specimens from a single surgery patient yielding stable smooth- as well as crepe-morphology isolates, we investigated the differences between five of them on a phenotypic and genomic level. In contrast to the initial assumption that they were switched forms of a clonal strain, karyotyping and genome sequencing showed that the patient was colonized by at least three distinct linages. Statistical analysis placed these groups distantly across the population of C. parapsilosis. Interestingly the single blood culture isolate was of smooth morphology and matched with an isolate from the patient’s nose of similar morphology. Strong variation between the isolates was seen in adhesin-encoding genes, where repeat regions showed significant variation in length and repeat-numbers, most strikingly in HWP1 of the smooth isolates. Although no differences in drug susceptibility were evident, the high phylogenetic distance separating the individual strains highlights the need for testing of multiple colonies in routine practice. The absence of biofilm formation in the blood stream isolate indicates a lack of respective adhesins in the cell wall, in turn pointing toward lack of adhesion as a positively contributing factor for dissemination."],["dc.identifier.doi","10.3389/fmicb.2020.01994"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17528"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83971"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-302X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Phenotypic Variability in a Coinfection With Three Independent Candida parapsilosis Lineages"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","150"],["dc.bibliographiccitation.journal","International Journal of Infectious Diseases"],["dc.bibliographiccitation.lastpage","159"],["dc.bibliographiccitation.volume","119"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Blei, Claudia"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Schulze, Marco H."],["dc.date.accessioned","2022-12-01T08:30:37Z"],["dc.date.available","2022-12-01T08:30:37Z"],["dc.date.issued","2022"],["dc.description.abstract","Background: Candidemia is rare and has a high mortality rate. This study analyses the impact of bedside antifungal stewardship (AFS) on clinical management and prognosis of patients with candidemia at a university hospital in Germany. Methods: All patients with at least one positive blood culture with Candida species between 2014 and 2016 received bedside AFS with standardized recommendations. Medical records were retrospectively an- alyzed. Results from the intervention period from 2014-2016 (n=109), with focus on 2016 (n=39), were compared with those from the pre-intervention period in 2013 (n=30). Results: Bedside AFS was performed in 24/35 (69%) surviving patients in 2016 within the first 3 days after diagnosis of candidemia. All surviving patients (n=35) in 2016 received antifungal treatment compared with 24/28 (86%) in 2013 (p=0.0344). Follow-up blood cultures were performed in 25/35 (71%) in 2016 compared with 10/25 (40%) in 2013 (p=0.0046). Survival in the intervention compared with the pre- intervention group did not differ significantly (p=0.58) one year after the diagnosis of candidemia was made. However, patients with candidemia often have multiple serious comorbidities. Conclusions: Individualized bedside AFS significantly improves adherence to recommendations for pa- tients with Candida fungemia, especially guideline-oriented diagnostics and therapy. Improving the prog- nosis of patients with candidemia remains a huge challenge for AFS."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1016/j.ijid.2022.03.054"],["dc.identifier.pii","S1201971222001916"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117935"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.issn","1201-9712"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","Impact of routine bedside infectious diseases service on clinical management and prognosis of patients with Candida fungemia – an example for Antifungal Stewardship at university level in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Antibiotics"],["dc.bibliographiccitation.volume","11"],["dc.contributor.affiliation","Euler, Maximilian; 1Department of Anesthesiology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; isabell.eickel@med.uni-goettingen.de (I.E.); johannes.wieditz@med.uni-goettingen.de (J.W.); konrad.meissner@med.uni-goettingen.de (K.M.); nils.kunze@med.uni-goettingen.de (N.K.-S.)"],["dc.contributor.affiliation","Perl, Thorsten; 2Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; thorsten.perl@med.uni-goettingen.de"],["dc.contributor.affiliation","Eickel, Isabell; 1Department of Anesthesiology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; isabell.eickel@med.uni-goettingen.de (I.E.); johannes.wieditz@med.uni-goettingen.de (J.W.); konrad.meissner@med.uni-goettingen.de (K.M.); nils.kunze@med.uni-goettingen.de (N.K.-S.)"],["dc.contributor.affiliation","Dudakova, Anna; 3Department of Medical Microbiology and Virology, University Medical Center Göttingen, Kreuzbergring 57, 37075 Göttingen, Germany; anna.dudakova@med.uni-goettingen.de (A.D.); esther.maguillarosado@med.uni-goettingen.de (E.M.R.)"],["dc.contributor.affiliation","Maguilla Rosado, Esther; 3Department of Medical Microbiology and Virology, University Medical Center Göttingen, Kreuzbergring 57, 37075 Göttingen, Germany; anna.dudakova@med.uni-goettingen.de (A.D.); esther.maguillarosado@med.uni-goettingen.de (E.M.R.)"],["dc.contributor.affiliation","Drees, Carolin; 4Leibniz-Institute for Analytical Sciences—ISAS—e.V., Bunsen-Kirchhoff-Straße 11, 44139 Dortmund, Germany; drees@medecon.ruhr (C.D.); w.vautz@ion-gas.de (W.V.)"],["dc.contributor.affiliation","Vautz, Wolfgang; 4Leibniz-Institute for Analytical Sciences—ISAS—e.V., Bunsen-Kirchhoff-Straße 11, 44139 Dortmund, Germany; drees@medecon.ruhr (C.D.); w.vautz@ion-gas.de (W.V.)"],["dc.contributor.affiliation","Wieditz, Johannes; 1Department of Anesthesiology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; isabell.eickel@med.uni-goettingen.de (I.E.); johannes.wieditz@med.uni-goettingen.de (J.W.); konrad.meissner@med.uni-goettingen.de (K.M.); nils.kunze@med.uni-goettingen.de (N.K.-S.)"],["dc.contributor.affiliation","Meissner, Konrad; 1Department of Anesthesiology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; isabell.eickel@med.uni-goettingen.de (I.E.); johannes.wieditz@med.uni-goettingen.de (J.W.); konrad.meissner@med.uni-goettingen.de (K.M.); nils.kunze@med.uni-goettingen.de (N.K.-S.)"],["dc.contributor.affiliation","Kunze-Szikszay, Nils; 1Department of Anesthesiology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; isabell.eickel@med.uni-goettingen.de (I.E.); johannes.wieditz@med.uni-goettingen.de (J.W.); konrad.meissner@med.uni-goettingen.de (K.M.); nils.kunze@med.uni-goettingen.de (N.K.-S.)"],["dc.contributor.author","Euler, Maximilian"],["dc.contributor.author","Perl, Thorsten"],["dc.contributor.author","Eickel, Isabell"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Maguilla Rosado, Esther"],["dc.contributor.author","Drees, Carolin"],["dc.contributor.author","Vautz, Wolfgang"],["dc.contributor.author","Wieditz, Johannes"],["dc.contributor.author","Meissner, Konrad"],["dc.contributor.author","Kunze-Szikszay, Nils"],["dc.date.accessioned","2022-08-04T08:39:16Z"],["dc.date.available","2022-08-04T08:39:16Z"],["dc.date.issued","2022-07-23"],["dc.date.updated","2022-08-03T09:06:01Z"],["dc.description.abstract","(1) Background: Automated blood culture headspace analysis for the detection of volatile organic compounds of microbial origin (mVOC) could be a non-invasive method for bedside rapid pathogen identification. We investigated whether analyzing the gaseous headspace of blood culture (BC) bottles through gas chromatography-ion mobility spectrometry (GC-IMS) enables differentiation of infected and non-infected; (2) Methods: BC were gained out of a rabbit model, with sepsis induced by intravenous administration of E. coli (EC group; n = 6) and control group (n = 6) receiving sterile LB medium intravenously. After 10 h, a pair of blood cultures was obtained and incubated for 36 h. The headspace from aerobic and anaerobic BC was sampled every two hours using an autosampler and analyzed using a GC-IMS device. MALDI-TOF MS was performed to confirm or exclude microbial growth in BCs; (3) Results: Signal intensities (SI) of 113 mVOC peak regions were statistically analyzed. In 24 regions, the SI trends differed between the groups and were considered to be useful for differentiation. The principal component analysis showed differentiation between EC and control group after 6 h, with 62.2% of the data variance described by the principal components 1 and 2. Single peak regions, for example peak region P_15, show significant SI differences after 6 h in the anaerobic environment (p < 0.001) and after 8 h in the aerobic environment (p < 0.001); (4) Conclusions: The results are promising and warrant further evaluation in studies with an extended microbial panel and indications concerning its transferability to human samples."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)"],["dc.description.sponsorship","APC support by the Open Access Publication Funds of the Göttingen University"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3390/antibiotics11080992"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112637"],["dc.language.iso","en"],["dc.relation.eissn","2079-6382"],["dc.rights","CC BY 4.0"],["dc.title","Blood Culture Headspace Gas Analysis Enables Early Detection of Escherichia coli Bacteremia in an Animal Model of Sepsis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]